-
Astral peptide Nectin-4 targeting PDC drug SC-101 was approved for clinical use in the United States
Zhuhai, China - On May 31, 2024, Starlink Biochem announced that its Nectin-4 targeted PDC drug, SC-101, has received clinical trial application (IND) approval from the US Food and Drug Administration (FDA).
2024-06-19
-
Astral peptide Nectin-4 targeting PDC drug SC-101 was approved for clinical use in the United States
Zhuhai, China - On May 31, 2024, Starlink Biochem announced that its Nectin-4 targeted PDC drug, SC-101, has received clinical trial application (IND) approval from the US Food and Drug Administration (FDA).
2024-06-19
-
Astral peptide Nectin-4 targeting PDC drug SC-101 was approved for clinical use in the United States
Zhuhai, China - On May 31, 2024, Starlink Biochem announced that its Nectin-4 targeted PDC drug, SC-101, has received clinical trial application (IND) approval from the US Food and Drug Administration (FDA).
2024-06-19